MarketPulse

multiple myeloma

12 articles
BenzingaBenzinga··Vandana Singh

Pfizer's ELREXFIO Demonstrates Superior Efficacy in Late-Stage Myeloma Trial

Pfizer's ELREXFIO cancer therapy shows superior efficacy in Phase 3 myeloma trial, but stock declines amid analyst skepticism about growth prospects.
PFEPhase 3 trialclinical trial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tempest's Dual-Targeting CAR-T Shows Promise as Clinical Data Update Looms

Tempest Therapeutics will present updated TPST-2003 CAR-T trial data at ISCT 2026, building on earlier 100% complete response rates in multiple myeloma patients.
TPSTclinical trialmultiple myeloma
BenzingaBenzinga··Vandana Singh

Sanofi Pursues First On-Body Injector Cancer Drug as FDA Extends Review

Sanofi seeks FDA approval for first on-body injector cancer therapy; decision extended to July 2026. Tzield pediatric indication also expanded.
SNYFDA approvalBiologics License Application
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Sarclisa Subcutaneous Formulation Wins CHMP Backing for EU Approval

Sanofi's isatuximab subcutaneous formulation gains European regulatory endorsement for multiple myeloma, offering patients first cancer treatment with portable injector option.
SNYmonoclonal antibodyclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson & Johnson

J&J Seeks EMA Approval for TECVAYLI as First-Line Monotherapy in Multiple Myeloma

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.
JNJEMA approvalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tempest Advances CAR-T Program With Manufacturing Deal Ahead of 2026 FDA Filing

Tempest Therapeutics partners with Cincinnati Children's for TPST-2003 manufacturing, targeting U.S. registrational study launch in 2026 following strong interim trial results.
TPSTclinical trialmultiple myeloma
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Bristol Myers' Abecma Poised for Explosive Growth as CAR-T Therapy Expands Beyond Relapsed Myeloma

Abecma CAR-T therapy market surging on rising myeloma cases and regulatory wins. BMS-backed treatment faces headwinds from tariffs but eyes earlier-line expansion.
BMYCELGrregulatory approvalmultiple myeloma
BenzingaBenzinga··Vandana Singh

J&J Wins FDA Nod for Multiple Myeloma Combo with Blockbuster 83% Survival Rate

FDA approves J&J's Tecvayli plus Darzalex Faspro for multiple myeloma with 83.3% three-year survival rate, expanding drug's label.
JNJPhase 3 clinical trialFDA approval
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Oncology-Focused Arcellx in $7.8B Cash Deal

Gilead acquires oncology firm Arcellx for $7.8 billion in cash, adding CAR T-cell cancer therapy to its pipeline. Deal expected to close Q4 2024.
GILDACLXacquisitionM&A
Investing.comInvesting.com··Timothy Fries

Gilead to Acquire Arcellx for $7.8B, Expanding CAR-T Therapy Portfolio

Gilead acquires Arcellx for $7.8B to expand CAR-T therapy portfolio, strengthening oncology pipeline and cell therapy capabilities.
GILDACLXacquisitionFDA approval
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Arcellx for $7.8B to Expand CAR-T Oncology Portfolio

Gilead acquires Arcellx for $7.8B to gain CAR-T therapy anito-cel for multiple myeloma, with FDA approval expected by late 2026.
GILDACLXacquisitionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Starton Advances Subcutaneous Lenalidomide Program With Phase 2a Multiple Myeloma Trial Launch

Starton launches Phase 2a trial for subcutaneous lenalidomide delivery in multiple myeloma, comparing three dose levels against standard oral Revlimid treatment.
BMYCELGrclinical developmentmultiple myeloma